{"id":3099,"date":"2017-06-30T14:37:09","date_gmt":"2017-06-30T12:37:09","guid":{"rendered":"https:\/\/www.farmaindustria.es\/web_en\/?p=3099"},"modified":"2017-06-30T14:37:09","modified_gmt":"2017-06-30T12:37:09","slug":"rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals","status":"publish","type":"post","link":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/","title":{"rendered":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals"},"content":{"rendered":"

Madrid, June 29, 2017.-<\/strong> In 2016, the pharmaceutical industry based in Spain invested approximately 194\u20ac million \u00a0in contracts with organizations and health professionals to develop R&D projects. \u00a0In addition, it contributed 112\u20ac million in aid to health professionals so that they could attend scientific-professional meetings and congresses; likewise, the health organizations that organize this type of event were given 81\u20ac million in support. \u00a0In general, the figures remain stable in relation to the previous year, the first in which these collaborations were published in research and medical training, which are essential pillars to underpin the R&D system of new medicines in Spain.
\nThe publication of this data is as a result\u00a0of the European transparency initiative adopted by companies adhering to the Code of Good Practices of the Pharmaceutical Industry in Spain. As with last year, during\u00a0these last days of June pharmaceutical companies have gone ahead with\u00a0publishing on their websites the value transfers derived from the collaborations made in 2016 with organizations and health professionals. \u00a0These two areas of research and training are supplemented by two other concepts: the provision of professional services, either individual or from organizations, worth 79\u20ac million, and the allocation\u00a0of grants, which can only be made to health organizations and totaled 35.5\u20ac million.
\nThe interaction between the pharmaceutical industry and healthcare organizations and professionals is fundamental for the investigation of new medicines and for the proper use of them. \u00a0This collaboration generates a positive dynamic for all: professionals, who update and improve their knowledge about medicines; industry, which benefits from the clinical and scientific experience of health workers; the health system, which has professionals at the forefront of knowledge and international biomedical research, as well as constant pharmacological improvements, and patients and society in general, the direct recipients of the provision of health services.
\nSince 2002, the pharmaceutical industry has had a Code of Good Practices, which regulates relations between industry and health professionals and organizations to introduce rigor, objectivity and independence into such relationships, which in turn avoids unfair competition between the companies. \u00a0This Code has been updated periodically with the incorporation of improvements derived from the experience in its application as well as the demands of our society. \u00a0The publication of the collaborations with professionals and organizations,\u00a0the outcome of a new modification of the Code carried out in 2014, coincides with\u00a0this ideas, which also seeks to generate confidence in society about the importance of these relationships.
\nSince the first publication was published last year, public institutions such as the Transparency and Good Governance Council and the National Commission on Markets and Competition, and private institutions, such as Transparency International Spain, have recognized the value of the initiative.
\nIn this data publication for 2016, aggregated and individualized data continue to coexist (depending on the consent of the professionals themselves), but in the following publication, which will take place in\u00a0June 2018 whilst also using\u00a02017 data, the entirety\u00a0of these collaborations will be made public in an individualized way in order to achieve maximum transparency. \u00a0In any case, the percentage of value transfers published on an individual basis has already grown significantly, from 20% to 35%, between 2015 and 2016, an increase that responds to the growing knowledge and endorsement of health professionals of the Transparency initiative adopted by the pharmaceutical industry with activity in Spain.
\nLeadership in R&D<\/strong>
\nThe sector’s investment in R&D in 2016 means it maintains it’s position as the absolute industrial leader in this field in Spain, with 1,085\u20ac million (8% more than in 2015). \u00a0Of this amount, 45% (about 493\u20ac million) went to research contracts outside the city, mainly with the public sector (research centers, hospitals, universities and other bodies), making the pharmaceutical industry the main driver of the biomedical public-private partnership in our country.<\/p>\n

The 194\u20ac million in R&D contracts with professionals and centers now published, account for about 40% of the total amount of these external collaborations and refer to collaborations for the design or execution of preclinical studies, clinical trials and post-authorization studies. \u00a0The remaining offshore investments include concepts such as preclinical research contracts in which no health professionals are involved or the provision of free medication for clinical trials and their monitoring.
\n“The important commitment made by the pharmaceutical industry to maintain research excellence has consolidated Spain as one of the best-equipped countries in Europe to host clinical trials, particularly in the early stages, which are the most complex and, in turn, allow for the early access to new therapies by patients, who are thus the main beneficiaries of this model,” says FARMAINDUSTRIA’s president Jes\u00fas Acebillo.
\nScientific training<\/strong>
\nOn the other hand, the 112\u20ac million with which the pharmaceutical industry contributes to the scientific and clinical training of professionals (a figure slightly lower than the 119\u20ac million seen in 2015) shows the sector’s willingness that Spanish health workers continue to maintain the highest level of knowledge which is especially important in the field of health, for the rapid advance in biomedical research and new treatments. \u00a0Scientific activities and congresses and scientific-professional meetings are the key instrument for this and the pharmaceutical industry is committed to making these possible.
\nIn 2016, the sector also supported health organizations in carrying out this type of activity with 81\u20ac million, an increase of 23% over the previous year. “The increase shows the commitment of the industry to the different health organizations and scientific societies, which are essential agents for sustaining our \u00a0R&D model of innovative medicines and guidance in training, a guarantee of independence of these activities,” says Acebillo. \u00a0“The work carried out by the societies in this area contributes to the fact that Spanish doctors have a level of excellence that has been recognized both nationally and internationally and that they carry out healthcare activity that is highly valued by citizens.”
\n93.4% of the aid allocated by the pharmaceutical industry in Spain to healthcare professionals is offered to doctors. \u00a0The country has 217,912 practicing doctors, according to official INE data for 2016, and a large number of them benefit from these scientific activities supported by the industry.<\/p>\n

It should be noted that only the average registration to a national scientific congress is 600-700\u20ac, an amount that can be increased if the meeting is international. \u00a0Last year, according to FARMAINDUSTRIA data, 76% of meetings in which the pharmaceutical industry collaborated were national, while the remaining 24% were international meetings.
\nThe congresses are of great importance to keep the doctor up to date on the advancements in his specialty, and every year thousands of specialists come to these scientific appointments both nationally and internationally. \u00a0Notwithstanding, the recent annual meeting of the American Society of Clinical Oncology has brought together more than 38,000 physicians in Chicago, while in Spain attendees at the major primary care societies, for example, stands at 7,000 attendees.
\nFor the president of FARMAINDUSTRIA, “the whole health system, and especially, of course, patients, benefits from the fact that specialists keep their knowledge up to date and know what the main novelties are in each therapeutic area; without forgetting that active participation in congresses can open the door to the participation of Spanish centers in international clinical trials, which at the same time attracts important investments and makes \u00a0early access of patients to new treatments possible. “In this context,” he adds, “here at\u00a0FARMAINDUSTRIA we understand that the pharmaceutical industry should cooperate with the health administration and organizations and professionals so that the training of specialists is the best possible for the benefit of society as a whole.”
\nValue of clinical experience<\/strong>
\nPayments to professionals and organizations for the provision of services amounted to 79\u20ac million in 2016, 10% less than in 2015. \u00a0They refer to guidance, consultancy and conference presentations and imply remuneration (which, if applicable, includes travel expenses and maintenance); its characteristics and requirements are delimited in the Code of Good Practices.
\nThese activities allow the pharmaceutical industry to be aware of\u00a0the behaviour in the clinical practice of medicines, an experience that only health professionals cherish. \u00a0From there, companies can improve the safety and efficacy of treatments or detect new needs, which is hugely beneficial for the treatment of diseases, for the efficiency of the system and, especially to provide solutions for the patient.
\nFinally, the pharmaceutical industry made donations and provided subsidies to health organizations providing social or humanitarian health care services worth 35.5\u20ac million, an increase of 8% over the previous year. \u00a0These contributions must respond to requests of the organizations themselves and are unrelated, since, as stated in the Code of Good Practices, they cannot constitute an incentive for “recommendation, prescription, purchase, supply, sale or administration of medicines.” This type of aid comes in various forms: from monetary contributions for research projects to donations of medicines to humanitarian institutions.
\nMore transparency, more confidence<\/strong>
\nThe publication of the collaborations between the pharmaceutical industry and health organizations and professionals, which is consolidated now for the second year, is a step forward in terms of the wager of the pharmaceutical industry for transparency, linked to the Code of Good Practices and materialized in 2002 with the creation of the Modern Self-Regulation System.
\nFramed in a continental initiative adopted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) – which belongs to FARMAINDUSTRIA – the publication of the collaborations aims to show society the value and importance of indispensable relations for advancement and prevent potential conflicts of interest that may arise with professionals. \u00a0Such relationships must always be based on objectivity, rigor and independence, principles that are covered by the Code of Good Practice, which is periodically adapted to the requirements of medical practice and a fair competition.
\n“The research and development of new drugs and their proper use would not be possible without the close collaboration between industry, health system and health organizations and professionals,” says Jesus Acebillo. The transparency initiative allows organizations, professionals and laboratories to show the value and importance of this collaboration and strengthen the trust of society, and in particular of patients. We all win.”<\/p>\n","protected":false},"excerpt":{"rendered":"

Madrid, June 29, 2017.- In 2016, the pharmaceutical industry based in Spain invested approximately 194\u20ac million \u00a0in contracts with organizations and health professionals to develop R&D projects. \u00a0In addition, it contributed 112\u20ac million in aid to health professionals so that they could attend scientific-professional meetings and congresses; likewise, the health organizations that organize this type …<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-3099","post","type-post","status-publish","format-standard","hentry","tema-code-of-good-practice-for-the-pharmaceutical-industry","tema-buenas-practicas","tema-salud","tema-sanidad","tema-gasto-hospitalario","tema-transparencia","area-id"],"acf":[],"yoast_head":"\nR&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria\" \/>\n<meta property=\"og:description\" content=\"Madrid, June 29, 2017.- In 2016, the pharmaceutical industry based in Spain invested approximately 194\u20ac million \u00a0in contracts with organizations and health professionals to develop R&D projects. \u00a0In addition, it contributed 112\u20ac million in aid to health professionals so that they could attend scientific-professional meetings and congresses; likewise, the health organizations that organize this type …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\" \/>\n<meta property=\"og:site_name\" content=\"FarmaIndustria\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-30T12:37:09+00:00\" \/>\n<meta name=\"author\" content=\"Nathalie Rooney\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:site\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nathalie Rooney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\"},\"author\":{\"name\":\"Nathalie Rooney\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\"},\"headline\":\"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals\",\"datePublished\":\"2017-06-30T12:37:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\"},\"wordCount\":1659,\"commentCount\":0,\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\",\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\",\"name\":\"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria\",\"isPartOf\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#website\"},\"datePublished\":\"2017-06-30T12:37:09+00:00\",\"author\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.farmaindustria.es\/web_en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#website\",\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/\",\"name\":\"FarmaIndustria\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.farmaindustria.es\/web_en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\",\"name\":\"Nathalie Rooney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"caption\":\"Nathalie Rooney\"},\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/author\/franfranco\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/","og_locale":"en_US","og_type":"article","og_title":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria","og_description":"Madrid, June 29, 2017.- In 2016, the pharmaceutical industry based in Spain invested approximately 194\u20ac million \u00a0in contracts with organizations and health professionals to develop R&D projects. \u00a0In addition, it contributed 112\u20ac million in aid to health professionals so that they could attend scientific-professional meetings and congresses; likewise, the health organizations that organize this type …","og_url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/","og_site_name":"FarmaIndustria","article_publisher":"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl","article_published_time":"2017-06-30T12:37:09+00:00","author":"Nathalie Rooney","twitter_card":"summary_large_image","twitter_creator":"@FarmaIndustria","twitter_site":"@FarmaIndustria","twitter_misc":{"Written by":"Nathalie Rooney","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#article","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/"},"author":{"name":"Nathalie Rooney","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"headline":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals","datePublished":"2017-06-30T12:37:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/"},"wordCount":1659,"commentCount":0,"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/","url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/","name":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals - FarmaIndustria","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#website"},"datePublished":"2017-06-30T12:37:09+00:00","author":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"breadcrumb":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2017\/06\/30\/rd-training-continue-basis-collaboration-pharmaceutical-industry-healthcare-professionals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.farmaindustria.es\/web_en\/"},{"@type":"ListItem","position":2,"name":"R&D and training continue to be the basis for collaboration between the pharmaceutical industry and healthcare professionals"}]},{"@type":"WebSite","@id":"https:\/\/www.farmaindustria.es\/web_en\/#website","url":"https:\/\/www.farmaindustria.es\/web_en\/","name":"FarmaIndustria","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.farmaindustria.es\/web_en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603","name":"Nathalie Rooney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","caption":"Nathalie Rooney"},"url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/author\/franfranco\/"}]}},"_links":{"self":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/3099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/comments?post=3099"}],"version-history":[{"count":1,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/3099\/revisions"}],"predecessor-version":[{"id":3100,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/3099\/revisions\/3100"}],"wp:attachment":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/media?parent=3099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}